• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Check-Cap Ltd.

    9/12/25 4:38:16 PM ET
    $CHEK
    Medical Electronics
    Health Care
    Get the next $CHEK alert in real time by email
    6-K 1 ea0257177-6k_check.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of September 2025

     

    Commission File Number: 001-36848

     

    Check-Cap Ltd.

    (Exact Name of Registrant as Specified in Charter)

     

    Abba Hushi Avenue

    P.O. Box 1271

    Isfiya, 30090 Mount Carmel, Israel

    (Address of principal executive offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

     

    Form 20-F ☒ Form 40-F ☐

     

     

     

     

     

    This Form 6-K is being incorporated by reference into Check-Cap Ltd.’s Registration Statements on Form F-3 (File No. 333-262401) and Form S-8 (File No. 333-203384, 333-226490 and 333-259666) filed with the Securities and Exchange Commission, to be a part thereof from the date on which this Report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

     

    Annual General Meeting of Shareholders

     

    Check-Cap Ltd. (the “Company”, or “Check-Cap”) will hold an Annual General Meeting of Shareholders on Friday, October 17, 2025, at 10:00 a.m., Eastern Time, at Paul Hastings LLP, 200 Park Avenue, New York, NY 10166. A copy of the Notice of the Annual General Meeting of Shareholders, the Proxy Statement as well as the Proxy Card are attached hereto as Exhibit 99.1, Exhibit 99.2 and Exhibit 99.3, respectively, and are incorporated herein by reference.

     

    Entry into a Material Definitive Agreement

     

    On September 12, 2025, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with MBody AI, a Nevada corporation (“MBody AI”), and CC Merger Sub Inc., a Nevada corporation and a direct, wholly owned subsidiary of Check-Cap (“Merger Sub”). Pursuant to the Merger Agreement, Merger Sub will merge with and into MBody AI, with MBody AI surviving as a wholly-owned subsidiary of Check-Cap (such transaction, the “Merger”).

     

    MBody AI is a market-leading artificial intelligence company redefining the future of work through embodied AI. MBody AI is not building robots; it is engineering the “brains of autonomy,” a proprietary AI stack that powers intelligent systems capable of learning, adapting, and optimizing in real time. From its initial focus in hospitality, MBody AI is positioned to expand across warehousing, office management, and healthcare. These verticals represent trillions of dollars in addressable labor spend, and MBody AI is strategically placed to scale rapidly into global markets.

     

    The combined company will be renamed “MBody AI Ltd.” or a similar name. Check-Cap’s legacy business will continue its research and development activities as part of the combined company. The combined company will continue to hold Check-Cap’s legacy assets, consisting primarily of patents and proprietary medical equipment.

     

    The Merger is also expected to complement and create potential synergies with Check-Cap’s Ghost Kitchen franchise rights in New Jersey. The Company expects the combined company to leverage shared technology, operational resources, and market relationships that will enable it to capitalize on the Ghost Kitchen franchise rights.

     

    Upon consummation of the Merger, each holder of shares of MBody AI common stock will receive, for each share of MBody AI common stock, ordinary shares of Check-Cap. Following the closing of the Merger, current MBody AI equityholders will own 90% of the issued and outstanding ordinary shares of the combined company on a fully diluted basis, and current Check-Cap equityholders will own 10% of the issued and outstanding ordinary shares of the combined company on a fully diluted basis.

     

    Subject to the satisfaction or waiver of the closing conditions set forth in the Merger Agreement, MBody AI and Check-Cap expect that the Merger will be consummated in the fourth quarter of 2025. However, it is possible that factors outside the control of both companies could result in the Merger being consummated at a different time, or not at all.

     

    In connection with the closing of the Merger, the Business Combination Agreement, dated as of March 25, 2024, by and between Check-Cap and Apollo Technology Capital Corporation (formerly known as Nobul AI Corp.), a private Ontario corporation (“Apollo”), will be terminated by mutual consent of the parties such that no termination fee will be due to Apollo or Check-Cap, so long as Check-Cap continues to be open to future integration with Apollo. Upon the closing of the Merger, the loans made by Check-Cap to Apollo that are currently outstanding will be converted into a 7.5% equity position in Apollo that will be owned by Check-Cap, and each of the related loan agreements between Check-Cap and Apollo will be cancelled for no further consideration.

     

    1

     

     

    The Merger Agreement contains customary representations, warranties and covenants made by the parties, including covenants relating to obtaining the requisite approvals of the security holders of Check-Cap, indemnification of directors and officers, and Check-Cap’s and MBody AI’s conduct of their respective businesses between the date of signing of the Merger Agreement and the closing.

     

    The closing of the Merger is subject to satisfaction or waiver of certain conditions including, among other things, (i) the expiration or termination of any waiting period applicable to the consummation of the Merger under any applicable antitrust law, (ii) the accuracy of representations and warranties under the Merger Agreement (subject to certain materiality exceptions), (iii) the absence of a material adverse effect on MBody AI or Check-Cap, (iv) MBody AI, Merger Sub and Check-Cap’s performance of their respective obligations under the Merger Agreement, and (v) the termination of any shareholders agreements, voting agreements, registration rights agreements, co-sale agreements and any other similar contracts between MBody AI and any holders of MBody AI’s capital stock.

     

    The Merger Agreement contains provisions granting both Check-Cap and MBody AI the right to terminate the Merger Agreement for certain reasons, including, among others, (i) by mutual consent, (ii) by either Check-Cap or MBody AI if the Merger fails to consummate by June 30, 2026, (iii) by either Check-Cap or MBody AI if shareholders of the Company fail to approve the Merger at the Meeting, (iv) by MBody AI if there is an adverse board recommendation of the board of directors of the Company (the “Board”), (v) by either Check-Cap or MBody AI upon a willful and material breach by either party, or (vi) by Check-Cap upon its decision to pursue permitted alternative transactions.

     

    MBody AI and Check-Cap have agreed that, upon the consummation of the Merger, the Board will be comprised of those individuals designated by MBody AI, provided, however, that Check-Cap will have the right to designate one (1) director. They have also agreed to use commercially reasonable efforts to secure a financing in a private placement on terms reasonably acceptable to each of the parties.

     

    The foregoing summary does not purport to be a complete description and is qualified in its entirety by reference to the full text of the Merger Agreement, which is attached hereto as Exhibit 99.4 and is incorporated herein by reference.

       

    Exhibit

     

    Exhibit No.   Description
    99.1   Notice for the Annual General Meeting of Shareholders.
    99.2   Proxy Statement for the Annual General Meeting of Shareholders.
    99.3   Proxy Card for the Annual General Meeting of Shareholders.
    99.4   Agreement and Plan of Merger, dated September 12, 2025, by and among Check-Cap Ltd., CC Merger Sub Inc. and MBody AI (included as Annex A to Exhibit 99.2).

     

    2

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      CHECK-CAP LTD.
      (Registrant)
         
    Date: September 12, 2025 By: /s/ David Lontini
      Name:  David Lontini
      Title: Interim Chief Executive Officer

     

    3

    Get the next $CHEK alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CHEK

    DatePrice TargetRatingAnalyst
    8/9/2021$4.00 → $3.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CHEK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MBody AI and Check-Cap Enter into Definitive Merger Agreement

    Merger to Create Combined Company Focused on Embodied AI for the Autonomous Workforce ISFIYA, ISRAEL, Sept. 12, 2025 (GLOBE NEWSWIRE) -- MBody AI ("MBody AI") and Check-Cap Ltd. ("Check-Cap" or the "Company") (NASDAQ:CHEK) today announced that they have entered into a definitive Agreement and Plan of Merger (the "Merger"). If the Merger is approved by Check-Cap shareholders, it will create a combined company focused on embodied AI for the autonomous workforce. Check-Cap's legacy business will continue its research and development activities as part of the combined company. MBody AI is a market-leading artificial intelligence ("AI") company redefining the future of work through embodied

    9/12/25 5:39:51 PM ET
    $CHEK
    Medical Electronics
    Health Care

    Check-Cap claims BMO's Chris Taves Illegally Attacks Israeli NASDAQ-Listed Company During Wartime

    Check-Cap Ltd. Issues Strong Condemnation of MediPharm Labs Chairman Chris Taves for Fabricated Defamatory Statements Press Releases Taves Times his Attack to Commence 23 Minutes before the Start of Shabbat to Delay the Company from Responding ISFIYA, ISRAEL, June 04, 2025 (GLOBE NEWSWIRE) -- Check-Cap Ltd. (NASDAQ:CHEK) ("Check-Cap" or the "Company"), a clinical-stage medical diagnostics company incorporated in Israel, today publicly condemned MediPharm Labs Corp. (LABS) ("MediPharm Labs") and its Chairman, Chris Taves, Head of Asia for BMO Capital Markets, for disseminating derogatory, false, and misleading statements about Check-Cap during a profoundly sensitive and challenging time

    6/4/25 7:00:00 AM ET
    $CHEK
    Medical Electronics
    Health Care

    Apollo Technology Capital Corporation Poses Questions That MediPharm Shareholders Should Ask on Management's Conference Call with Shareholders

    Company Has Suspended Calls Since the Second Quarter of 2024 to Avoid Facing the Music for Board's and Management Team's Destruction of 99% of Stock's Value, Costing Shareholders $1 Billion  Conference Call is a Blatant, Self-Serving Reaction by a Management Team Running Scared Following Apollo Capital's Intention to Nominate Six Highly Qualified Directors to MediPharm's Board  Shareholders Deserve Answers From Management About Massive Underperformance, Failed Operational Strategies, Poor Capital Allocation, Outrageous Compensation, and Lack of Transparency Apollo Capital's Nominees Bring Significant Turnaround, M&A, and Operational Experience in Cannabis and Adjacent Industries, and Will Ex

    5/14/25 8:30:00 AM ET
    $CHEK
    Medical Electronics
    Health Care

    $CHEK
    SEC Filings

    View All

    SEC Form 6-K filed by Check-Cap Ltd.

    6-K - Check-Cap Ltd (0001610590) (Filer)

    9/12/25 4:38:16 PM ET
    $CHEK
    Medical Electronics
    Health Care

    SEC Form 6-K filed by Check-Cap Ltd.

    6-K - Check-Cap Ltd (0001610590) (Filer)

    9/5/25 4:30:29 PM ET
    $CHEK
    Medical Electronics
    Health Care

    SEC Form 20-F filed by Check-Cap Ltd.

    20-F - Check-Cap Ltd (0001610590) (Filer)

    8/26/25 8:59:38 PM ET
    $CHEK
    Medical Electronics
    Health Care

    $CHEK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. reiterated coverage on Check-Cap with a new price target

    HC Wainwright & Co. reiterated coverage of Check-Cap with a rating of Buy and set a new price target of $3.00 from $4.00 previously

    8/9/21 6:35:25 AM ET
    $CHEK
    Medical Electronics
    Health Care

    Check-Cap downgraded by Dawson James with a new price target

    Dawson James downgraded Check-Cap from Buy to Neutral and set a new price target of $2.00

    3/17/21 12:12:30 PM ET
    $CHEK
    Medical Electronics
    Health Care

    HC Wainwright & Co. reiterated coverage on Check-Cap with a new price target

    HC Wainwright & Co. reiterated coverage of Check-Cap with a rating of Buy and set a new price target of $4.00 from $1.50 previously

    3/16/21 6:31:50 AM ET
    $CHEK
    Medical Electronics
    Health Care

    $CHEK
    Leadership Updates

    Live Leadership Updates

    View All

    Symetryx Today Issues Open Letter to Shareholders In Regard to the Upcoming Annual General Meeting

    Recommends Fellow Shareholders Vote AGAINST Keystone Transaction & the Check-Cap Board Nominees - Further Recommends a Vote FOR the Symetryx Slate of Director Candidates Cites Unrealistic and Aggressive Valuation of Keystone Used to Justify the Merger and Troubling Cash Burn by Check-Cap Board & Management TORONTO, Nov. 28, 2023 /PRNewswire/ - Symetryx, a holder of 5.6% of Check-Cap Ltd. (NASDAQ:CHEK) shares, today issued the following open letter to shareholders. In the letter Symetryx cites, among other items, its serious concerns and reason for voting AGAINST the proposed transaction with Keystone Dental.  Symetryx discusses its concerns around the actions of the Board in its evaluation

    11/28/23 11:56:00 AM ET
    $CHEK
    Medical Electronics
    Health Care

    Check-Cap Appoints Dr. Hanit Brenner-Lavie as Vice President of Clinical Affairs

    ISFIYA, Israel, Sept. 1, 2021 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ:CHEK), (NASDAQ:CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test to detect polyps before they may transform into colorectal cancer (CRC), today announced the appointment of Dr. Hanit Brenner-Lavie as Vice President of Clinical Affairs. Dr. Brenner-Lavie will be responsible for leading the Company's overall clinical strategy and implementation as well as driving the Company's clinical direction, including innovation. "Dr. Brenner-Lavie has a proven track record of clinical strategy dev

    9/1/21 8:30:00 AM ET
    $CHEK
    Medical Electronics
    Health Care

    $CHEK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Check-Cap Ltd. (Amendment)

    SC 13D/A - Check-Cap Ltd (0001610590) (Subject)

    4/8/24 7:35:32 PM ET
    $CHEK
    Medical Electronics
    Health Care

    SEC Form SC 13D filed by Check-Cap Ltd.

    SC 13D - Check-Cap Ltd (0001610590) (Subject)

    4/1/24 9:26:38 PM ET
    $CHEK
    Medical Electronics
    Health Care

    SEC Form SC 13D/A filed by Check-Cap Ltd. (Amendment)

    SC 13D/A - Check-Cap Ltd (0001610590) (Subject)

    12/18/23 6:07:13 AM ET
    $CHEK
    Medical Electronics
    Health Care

    $CHEK
    Financials

    Live finance-specific insights

    View All

    Apollo Technology Capital Corporation Poses Questions That MediPharm Shareholders Should Ask on Management's Conference Call with Shareholders

    Company Has Suspended Calls Since the Second Quarter of 2024 to Avoid Facing the Music for Board's and Management Team's Destruction of 99% of Stock's Value, Costing Shareholders $1 Billion  Conference Call is a Blatant, Self-Serving Reaction by a Management Team Running Scared Following Apollo Capital's Intention to Nominate Six Highly Qualified Directors to MediPharm's Board  Shareholders Deserve Answers From Management About Massive Underperformance, Failed Operational Strategies, Poor Capital Allocation, Outrageous Compensation, and Lack of Transparency Apollo Capital's Nominees Bring Significant Turnaround, M&A, and Operational Experience in Cannabis and Adjacent Industries, and Will Ex

    5/14/25 8:30:00 AM ET
    $CHEK
    Medical Electronics
    Health Care

    Keystone Dental Group Granted Patent from USPTO for Nexus IOS Solution

    IRVINE, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Osteon Medical, a subsidiary of Keystone Dental Holdings ("Keystone Dental" or the "Company"), today announced the United States Patent and Trademark Office (USPTO) has granted the Company a patent for its innovative Nexus IOS solution. The Nexus iOS Scan Gauge technology allows implant dentists to perform direct full-arch implant scans using an Intraoral Scanner (IOS) with predictable and passive fitting prosthetic outcomes. This technology replaces the traditionally manual impression-taking process through a faster, cost-effective, and accessible workflow. The Nexus iOS Scan Gauge technology is now the only patented elongated body scan

    10/18/23 4:05:00 PM ET
    $CHEK
    Medical Electronics
    Health Care

    Keystone Dental Holdings and Check-Cap Ltd Enter into Definitive Business Combination Agreement

    Proposed business combination to create a Nasdaq-listed medical device company focused on advancing the commercial execution and market development of Keystone's comprehensive portfolio of implants, arches and other tooth replacement solutions Keystone 2022 revenues exceeded $60 million The combined company will trade on the NASDAQ with the ticker "KSD" Investor conference call and webcast scheduled for 8:30 a.m. ET on Thursday, August 17th IRVINE, Calif. and BURLINGTON, Mass., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Keystone Dental Holdings, Inc. ("Keystone Dental") and Check-Cap Ltd. ("Check-Cap" or the "Company") (NASDAQ:CHEK) today announced that they have entered into a definitive Busin

    8/16/23 5:08:47 PM ET
    $CHEK
    Medical Electronics
    Health Care